Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia

CSE-1034 is a novel antibiotic adjuvant entity (AAE) with proven activity against broad range of multi-drug resistant (MDR) pathogens causing various bacterial infections. This phase 3 clinical trial was designed to evaluate the efficacy and safety of CSE-1034 therapy for the treatment of community-acquired pneumonia (CAP) patients of Pneumonia Outcomes Research Team (PORT) risk III –IV.
Source: Journal of Infection and Public Health - Category: International Medicine & Public Health Authors: Source Type: research